Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis Pharmaceuticals IONS has entered into a licensing agreement with Otsuka Pharmaceutical. Per the terms, Otsuka will acquire exclusive rights to market its investigational late-stage hereditary angioedema (HAE) therapy, donidalorsen, in the Asia-Pacific region. This agreement is an expansion of...